Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Shares Gap Down – Time to Sell?

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY)’s share price gapped down prior to trading on Thursday . The stock had previously closed at $9.40, but opened at $8.83. Shionogi & Co., Ltd. Unsponsored ADR shares last traded at $9.20, with a volume of 497 shares traded.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. Jefferies Financial Group upgraded Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 14th. The Goldman Sachs Group upgraded shares of Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a report on Monday, June 15th. Two research analysts have rated the stock with a Strong Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Buy”.

Shionogi & Co., Ltd. Unsponsored ADR Stock Performance

The firm has a 50-day simple moving average of $9.07 and a two-hundred day simple moving average of $9.47. The company has a current ratio of 1.14, a quick ratio of 1.00 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $15.57 billion, a price-to-earnings ratio of 9.15, a price-to-earnings-growth ratio of 3.37 and a beta of 0.08.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) last released its quarterly earnings data on Monday, August 3rd. The company reported $0.36 EPS for the quarter, topping analysts’ consensus estimates of $0.18 by $0.18. The firm had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $970.69 million. Shionogi & Co., Ltd. Unsponsored ADR had a return on equity of 16.13% and a net margin of 46.67%. As a group, sell-side analysts forecast that Shionogi & Co., Ltd. Unsponsored ADR will post 0.82 earnings per share for the current fiscal year.

About Shionogi & Co., Ltd. Unsponsored ADR

Shionogi & Co, Ltd. is a Japan-based pharmaceutical company that researches, develops, manufactures and markets prescription medicines. Founded in Osaka in 1878, the company has built its business around drug discovery and has a particular focus on infectious diseases, including antiviral and antibacterial treatments.

Shionogi’s products include Xofluza (baloxavir marboxil), an oral treatment for influenza, and Fetcroja (cefiderocol), an antibiotic used for certain difficult-to-treat bacterial infections.